Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study

Clin Exp Dermatol. 2005 Nov;30(6):632-5. doi: 10.1111/j.1365-2230.2005.01908.x.

Abstract

Rosacea is a chronic facial dermatosis with a progressive course, which is characterized by the presence of erythema, papules, pustules, telangiectasias and sebaceous gland hyperplasia. However, the aetiology is still unknown; genetic predisposition, gastrointestinal disorders (Helicobacter pylori), infestations with Demodex folliculorum and environmental stimuli are considered to be involved in the inflammatory process. A metabolite of nicotinamide, 1-methylnicotinamide (MNA(+)), has anti-inflammatory properties, and this is the first study to test the effectiveness of this agent in treating rosacea. In total, 34 patients with rosacea were treated with a gel containing 0.25% MNA(+) as a chloride salt, twice daily for 4 weeks, after which improvement was observed in 26/34 cases. The improvement was good in 9/34 and moderate in 17/34, but no clinical effect was noted in seven subjects. In only one case was skin irritation given as the reason for treatment withdrawal. These results indicate that MNA(+) might be a useful agent for treating rosacea.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Chronic Disease
  • Dermatologic Agents / administration & dosage*
  • Facial Dermatoses / drug therapy*
  • Female
  • Gels
  • Humans
  • Male
  • Middle Aged
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives*
  • Pilot Projects
  • Rosacea / drug therapy*

Substances

  • Dermatologic Agents
  • Gels
  • Niacinamide
  • N(1)-methylnicotinamide